



# Spinraza in India

*The CDSCO named-patient coordination pathway — indicative 2026*

RARE DISEASE · INTRATHECAL ASO FOR SMA

## The clinical situation

Spinraza (nusinersen) is an antisense oligonucleotide modulating SMN2 splicing for spinal muscular atrophy across the paediatric and adult age spectrum. Manufactured by Biogen. Delivered by intrathecal injection 12 mg: four loading doses at days 0, 14, 28, and 63, then maintenance every four months for life. Requires a qualified interventional team; platelets and coagulation are monitored given post-lumbar puncture bleeding risk.

### The pathway, 5 steps

- 1 Consultation & SMN1 genotyping.** Your neurology team confirms biallelic SMN1 deletion/mutation and documents motor and respiratory baseline.
- 2 Baseline assessment.** Platelet count, coagulation profile, renal function, and spine imaging to plan intrathecal access.
- 3 CDSCO named-patient application.** Clinical rationale, genotype report, and planned intrathecal-administration centre filed under personal-use import.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates dose-by-dose supply through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Administration & continuity.** Interventional neurology/radiology team performs intrathecal dosing on schedule; platelet/coagulation monitoring per FDA labelling.

### Indicative economics

**Reference US cash-pay range:** USD 125,000–140,000 per 12 mg dose; Year 1 typically 6 doses (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete CDSCO application to first dose, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your neurology team and CDSCO review, keyed to SMN1 genotype and administration centre. **Logistics.** Temperature-controlled shipment with importer-of-record handling and continuity planning for every maintenance dose. **Concierge case lead.** Named point of contact for the family and care team. **We are a coordinator** — not the prescriber, not the administering centre. All clinical decisions remain with your treating neurologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Spinraza × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/spinraza-india.html](https://reservemed.com/access-guides/spinraza-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team